Evolent Health (EVH)
(Real Time Quote from BATS)
$22.65 USD
+0.46 (2.07%)
Updated Jul 26, 2024 09:50 AM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVH 22.65 +0.46(2.07%)
Will EVH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVH
Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
Other News for EVH
10 Health Care Stocks Whale Activity In Today's Session
RBC Capital Keeps Their Buy Rating on Evolent Health (EVH)
Interesting EVH Put And Call Options For March 2025
Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
First Week of August 16th Options Trading For Evolent Health (EVH)